SOLUBLE T-CELL ANTIGEN RECEPTORS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 474

transfer of genetically engineered lymphocytes. Science 314,
126-129.
67. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM,
Dudley ME, et al. (2011) Tumor regression in patients with
metastatic synovial cell sarcoma and melanoma using geneti-
cally engineered lymphocytes

72. Michaeli Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C,
Beauverd C, et al. (2009) Expression hierarchy of T cell
epitopes from melanoma differentiation antigens: unexpected
high level presentation of tyrosinase-HLA-A2 Complexes
revealed by peptide-specific, MHC-restricted, TCR-like anti-
bodies. J. Immunol. 182, 6328-6341.
73. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME,
Mahon TM, et al. (2006) Quantifying and imaging NY-ESO-
1/LAGE-1-derived epitopes on tumor cells using high affinity
T cell receptors. J. Immunol. 176, 7308-7316.
74. Purbhoo MA, Li Y, Sutton DH, Brewer JE, Gostick E, Bossi G,
et al. (2007) The HLA A 0201-restricted hTERT(540-548)
peptide is not detected on tumor cells by a CTL clone or a high-
affinity T-cell receptor. Mol. Cancer Ther. 6, 2081-2091.
75. Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-
Internati M, Hildebrand WH, et al. (2006) Levels of specific
peptide-HLA class I complex predicts tumor cell susceptibility
to CTL killing. J. Immunol. 177, 5088-5097.
76. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M,
Paxton R, Anderson D, et al. (1994) Interleukin (IL) 15 is
a novel cytokine that activates human natural killer cells
via components of the IL-2 receptor. J. Exp. Med. 180,
1395-1403.

reactive with NY-ESO-1.

J. Clin. Oncol. 29, 917-924.
68. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan
DA, Feldman SA, et al. (2011) T cells targeting carcinoem-
bryonic antigen can mediate regression of metastatic colo-
rectal cancer but induce severe transient colitis. Mol. Ther.
19, 620-626.
69. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA,
Yun GH, Fautsch SK, et al. (2005) Successful adoptive transfer
and in vivo expansion of human haploidentical NK cells in
patients with cancer. Blood 105, 3051-3057.
70. Soussi T, Beroud C. (2003) Significance of TP53 mutations in
human cancer: a critical analysis of mutations at CpG dinu-
cleotides. Hum. Mutat. 21, 192-200.
71. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin
PM, Hortobagyi GN. (2009) The HER-2 receptor and breast
cancer: ten years of targeted Anti-HER-2 therapy and person-
alized medicine. Oncologist 14, 320-368.